Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurol. 2011 Feb;258(2):218-22. doi: 10.1007/s00415-010-5721-2. Epub 2010 Aug 29.

Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations.

Author information

  • 1Rudolf Magnus Institute of Neuroscience, Department of Neurology, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands. n.a.visser-3@umcutrecht.nl

Abstract

Mutations in the gene encoding of the catalytic subunit of mtDNA polymerase gamma (POLG1) can cause typical Alpers' syndrome. Recently, a new POLG1 mutation phenotype was described, the so-called juvenile-onset Alpers' syndrome. This POLG1 mutation phenotype is characterized by refractory epilepsy with recurrent status epilepticus and episodes of epilepsia partialis continua, which often necessitate admission to the intensive care unit (ICU) and pose an important mortality risk. We describe two previously healthy unrelated teenage girls, who both were admitted with generalized tonic-clonic seizures and visual symptoms leading to a DNA-supported diagnosis of juvenile-onset Alpers' syndrome. Despite combined treatment with anti-epileptic drugs, both patients developed status epilepticus requiring admission to the ICU. Intravenous magnesium as anti-convulsant therapy was initiated, resulting in clinical and neurophysiological improvement and rapid extubation of both patients. Treating status epilepticus in juvenile-onset Alpers' syndrome with magnesium has not been described previously. Given the difficulties encountered while treating epilepsy in patients with this syndrome, magnesium therapy might be considered.

PMID:
20803213
[PubMed - indexed for MEDLINE]
PMCID:
PMC3036811
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk